Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 4

Conditions

Ovarian Neoplasms 92Breast Neoplasms 69Prostatic Neoplasms 33Triple Negative Breast Neoplasms 32Neoplasms 26Fallopian Tube Neoplasms 25Neoplasm Metastasis 21Endometrial Neoplasms 19Pancreatic Neoplasms 18Small Cell Lung Carcinoma 13Carcinoma, Ovarian Epithelial 12Carcinoma, Non-Small-Cell Lung 10Stomach Neoplasms 9Sarcoma 9Recurrence 9Lung Neoplasms 9Fanconi Anemia, Complementation Group D1 9Squamous Cell Carcinoma of Head and Neck 8Glioma 8Parkinson Disease 4, Autosomal Dominant Lewy Body 7Glioblastoma 7Colorectal Neoplasms 6Metastatic Castration-resistant Prostate Cancer 5Lymphoma, Non-Hodgkin 5Cholangiocarcinoma 5Carcinoma, Renal Cell 5Uterine Cervical Neoplasms 4Urinary Bladder Neoplasms 4Solid Tumors 4Osteosarcoma 4

Interventions

Paclitaxel 15atezolizumab 11Gemcitabine 11Carboplatin 9pembrolizumab 8Docetaxel 8Bevacizumab 8Irinotecan 7Injections 6Cetuximab 6Capecitabine 6Sunitinib 5Leucovorin 5Fluorouracil 5Cyclophosphamide 5tocilizumab 4pazopanib 4olaparib 4navitoclax 4liposomal doxorubicin 4Topotecan 4Oxaliplatin 4Nivolumab 4Erlotinib Hydrochloride 4temsirolimus 3spartalizumab 3lenvatinib 3fludarabine 3cobimetinib 3Cisplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Solid Tumors × olaparib × Clear all
NCT00777582 2026-05-08

Phase I Comparative Bioavailability Study

AstraZeneca

Phase 1 Active not recruiting
197 enrolled
Other solid neoplasm

Solid Tumors

NCT04123366 2026-04-22

MK-7339-007

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
300 enrolled
Other solid neoplasm

Solid Tumors

NCT07018622 2026-03-11

DAPA-ARMOR

Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

Phase 2 Recruiting
46 enrolled
Other solid neoplasm

Solid Tumors

NCT00819221 2022-08-30

AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours

AstraZeneca

Phase 1 Terminated
44 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡